• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人 T 细胞白血病/淋巴瘤和外周 T 细胞淋巴瘤-非特指型发病率增加,整体生存情况改善有限:基于人群的大阪癌症登记处数据的回顾性分析。

Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.

机构信息

Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

出版信息

Ann Hematol. 2021 Jan;100(1):157-165. doi: 10.1007/s00277-020-04308-8. Epub 2020 Oct 21.

DOI:10.1007/s00277-020-04308-8
PMID:33089366
Abstract

Peripheral T cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas with poor outcomes. Adult T cell leukemia-lymphoma (ATL) and PTCL-not otherwise specified (PTCL-NOS)-are 2 common mature T cell lymphomas in Japan. Since it is unclear whether novel agents and treatment strategies incorporating hematopoietic cell transplantation have contributed to improved clinical outcomes in the real world, we performed a retrospective analysis using data from the population-based Osaka Cancer Registry. From 1977 to 2014, 1274 and 1143 patients were diagnosed with ATL or PTCL-NOS, respectively. Recently, the incidence of both diseases has gradually increased, and the age at diagnosis has risen. The 3-year overall survival (OS) rates in ATL patients were 12.0% in era 1 (1977-1999), 12.4% in era 2 (2000-2008), and 17.5% in era 3 (2009-2014) (P < 0.001). The 3-year OS rates in PTCL-NOS patients were 27.6% in era 1, 36.2% in era 2, and 35.0% in era 3 (P = 0.049). In conclusion, the incidences of ATL and PTCL-NOS have been increasing, particularly in elderly individuals. Clinical outcomes have improved in recent decades but are still unsatisfactory in both diseases. Thus, effective new treatment strategies incorporating novel agents are needed to further improve clinical outcomes in patients with ATL and PTCL-NOS.

摘要

外周 T 细胞淋巴瘤 (PTCL) 是一组异质性非霍奇金淋巴瘤,预后较差。成人 T 细胞白血病/淋巴瘤 (ATL) 和未特指的 PTCL-NOS (PTCL-NOS) 是日本 2 种常见的成熟 T 细胞淋巴瘤。由于尚不清楚新型药物和包含造血细胞移植的治疗策略是否有助于改善真实世界中的临床结局,我们使用基于人群的大阪癌症登记处的数据进行了回顾性分析。1977 年至 2014 年,分别诊断出 1274 例和 1143 例 ATL 或 PTCL-NOS 患者。最近,这两种疾病的发病率逐渐增加,诊断时的年龄也在上升。ATL 患者的 3 年总生存 (OS) 率在 1 时代 (1977-1999 年) 为 12.0%,2 时代 (2000-2008 年) 为 12.4%,3 时代 (2009-2014 年) 为 17.5%(P < 0.001)。PTCL-NOS 患者的 3 年 OS 率在 1 时代为 27.6%,2 时代为 36.2%,3 时代为 35.0%(P = 0.049)。总之,ATL 和 PTCL-NOS 的发病率一直在增加,尤其是在老年人中。近几十年来,临床结局有所改善,但在这两种疾病中仍然不尽如人意。因此,需要包含新型药物的有效新治疗策略来进一步改善 ATL 和 PTCL-NOS 患者的临床结局。

相似文献

1
Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.成人 T 细胞白血病/淋巴瘤和外周 T 细胞淋巴瘤-非特指型发病率增加,整体生存情况改善有限:基于人群的大阪癌症登记处数据的回顾性分析。
Ann Hematol. 2021 Jan;100(1):157-165. doi: 10.1007/s00277-020-04308-8. Epub 2020 Oct 21.
2
Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.皮下脂膜炎样T细胞淋巴瘤和未另行指定的外周T细胞淋巴瘤的生存情况:监测、流行病学和最终结果数据库的倾向匹配分析
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):373-8. doi: 10.1016/j.clml.2016.04.015. Epub 2016 May 4.
3
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.T细胞幼淋巴细胞白血病与外周T细胞淋巴瘤(未另行指定)临床病理特征的比较
Eur J Haematol. 2017 May;98(5):459-466. doi: 10.1111/ejh.12856. Epub 2017 Mar 3.
4
Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India.印度南部一家三级医疗中心外周T细胞淋巴瘤(未另行指定)的发病率、分布及免疫形态学特征
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):204-208. doi: 10.4103/IJPM.IJPM_405_17.
5
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.异质性外周 T 细胞淋巴瘤和血管免疫母细胞性 T 细胞淋巴瘤患者干细胞移植的疗效。
Int J Hematol. 2020 Jul;112(1):74-83. doi: 10.1007/s12185-020-02879-w. Epub 2020 Apr 15.
6
A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified.较低的绝对淋巴细胞计数/绝对单核细胞计数比值与外周T细胞淋巴瘤(非特指型)的不良预后相关。
Leuk Res. 2018 Oct;73:5-11. doi: 10.1016/j.leukres.2018.07.020. Epub 2018 Jul 26.
7
Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.未特指的皮肤外周 T 细胞淋巴瘤:一项单中心预后分析。
J Am Acad Dermatol. 2016 Nov;75(5):992-999. doi: 10.1016/j.jaad.2016.06.011. Epub 2016 Aug 4.
8
Clinical Outcomes of Patients with Adult T Cell Leukemia-Lymphoma in a Nonendemic Metropolitan Area: A Retrospective Analysis of the Population-Based Osaka Cancer Registry.非流行地区成人 T 细胞白血病/淋巴瘤患者的临床结局:基于人群的大阪癌症登记处的回顾性分析。
Biol Blood Marrow Transplant. 2020 Aug;26(8):1433-1438. doi: 10.1016/j.bbmt.2020.04.019. Epub 2020 May 15.
9
Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.血清IgA水平、单核细胞计数和国际预后指数与HTLV-I阴性淋巴结外周T细胞淋巴瘤患者的总生存期独立相关。
Ann Hematol. 2014 Jul;93(7):1185-91. doi: 10.1007/s00277-014-2025-0. Epub 2014 Feb 14.
10
Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).外周T细胞淋巴瘤,非特指型(PTCL-NOS)。
Cancer Treat Res. 2019;176:83-98. doi: 10.1007/978-3-319-99716-2_4.

引用本文的文献

1
Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.东京治疗成人T细胞白血病/淋巴瘤的核心医院中70岁及以下侵袭性成人T细胞白血病/淋巴瘤患者的治疗结果。
Int J Hematol. 2025 Sep 2. doi: 10.1007/s12185-025-04057-2.
2
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).目前外周 T 细胞淋巴瘤患者的治疗模式和 upfront 自体干细胞移植的作用:一项韩国全国性、多中心前瞻性注册研究(CISL 1404)。
Cancer Res Treat. 2023 Apr;55(2):684-692. doi: 10.4143/crt.2022.1434. Epub 2023 Jan 2.
3

本文引用的文献

1
Hospital volume and postoperative 5-year survival for five different cancer sites: A population-based study in Japan.医院容量与五个不同癌症部位的术后 5 年生存率:日本一项基于人群的研究。
Cancer Sci. 2020 Mar;111(3):985-993. doi: 10.1111/cas.14309. Epub 2020 Feb 3.
2
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.修订版成人 T 细胞白血病-淋巴瘤国际共识会议报告。
J Clin Oncol. 2019 Mar 10;37(8):677-687. doi: 10.1200/JCO.18.00501. Epub 2019 Jan 18.
3
Mogamulizumab investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
基于大阪癌症登记处的真实世界数据,分析急性髓系白血病患者的临床结局的长期趋势。
Ann Hematol. 2021 Nov;100(11):2717-2725. doi: 10.1007/s00277-021-04631-8. Epub 2021 Sep 3.
莫格利珠单抗治疗复发/难治性成人 T 细胞白血病/淋巴瘤的化疗方案选择。
Haematologica. 2019 May;104(5):993-1003. doi: 10.3324/haematol.2018.205096. Epub 2018 Dec 20.
4
Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients.合并症对胃癌、结直肠癌和肺癌患者生存的影响。
J Epidemiol. 2019 Mar 5;29(3):110-115. doi: 10.2188/jea.JE20170241. Epub 2018 Jul 14.
5
Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP.优化外周T细胞淋巴瘤的初始治疗:CHOP方案面临的难题
Lancet Haematol. 2018 May;5(5):e182-e183. doi: 10.1016/S2352-3026(18)30047-4.
6
Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.异基因造血干细胞移植治疗 T 细胞淋巴瘤。
Blood. 2018 Jul 19;132(3):245-253. doi: 10.1182/blood-2018-01-791335. Epub 2018 Apr 26.
7
Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.一项关于单纯化疗或化疗联合莫加莫拉单抗治疗新诊断的侵袭性成人T细胞白血病-淋巴瘤的随机II期研究的随访:对异基因造血干细胞移植的影响
Br J Haematol. 2019 Feb;184(3):479-483. doi: 10.1111/bjh.15123. Epub 2018 Feb 7.
8
Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.upfront异基因造血干细胞移植在侵袭性成人T细胞白血病-淋巴瘤患者中的作用:一项决策分析
Bone Marrow Transplant. 2018 Jul;53(7):905-908. doi: 10.1038/s41409-017-0082-4. Epub 2018 Jan 25.
9
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.成熟 T 细胞和 NK/T 细胞淋巴瘤造血细胞移植适应证和时机的临床实践推荐:代表美国血液和骨髓移植学会指南委员会的国际合作努力。
Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.
10
Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.莫格利珠单抗治疗复发的成人T细胞白血病-淋巴瘤:I期和II期研究的更新随访分析
Cancer Sci. 2017 Oct;108(10):2022-2029. doi: 10.1111/cas.13343. Epub 2017 Aug 28.